Trulicity and PPIs (Omeprazole, Pantoprazole): Interaction Guide

Is There an Interaction Between Trulicity and PPIs?

The Trulicity drug interactions section covers two things: oral medications in general, because dulaglutide delays gastric emptying, and insulin secretagogues or insulin, because of hypoglycemia risk [1]. The only oral drug the label names is warfarin, as the example of a narrow-therapeutic-index medication whose levels should be monitored [1]. Proton pump inhibitors do not appear anywhere in that section.

The Nexium label, which covers esomeprazole (the S-enantiomer of omeprazole), lists interactions in the other direction. Its interaction table covers clopidogrel, warfarin, methotrexate, antiretrovirals such as rilpivirine (contraindicated with every PPI), drugs that need stomach acid to be absorbed, and CYP2C19 substrates such as citalopram and cilostazol [2]. Dulaglutide does not appear in that table.

Not being listed is not the same as having been tested and cleared.

How Dulaglutide and PPIs Are Handled in the Body

Dulaglutide is a human GLP-1 receptor agonist with 90% amino acid sequence homology to endogenous GLP-1(7-37). It raises intracellular cAMP in pancreatic beta cells to release insulin in a glucose-dependent way, reduces glucagon secretion, and slows gastric emptying [1]. Its bioavailability is 65% at 0.75 mg and 47% at 1.5 mg, its half-life is about 5 days, and it is presumed to be degraded into amino acids by general protein catabolism; age, sex, race, body weight and renal or hepatic impairment have no clinically relevant effect on how it is handled [1].

PPIs are small molecules that block the parietal cell H+/K+ ATPase, the proton pump that makes stomach acid [2]. Their acid suppression lasts far longer than their plasma half-life (omeprazole 0.5 to 1 hour, pantoprazole about 1 hour, esomeprazole 1 to 1.5 hours, lansoprazole under 2 hours) because they stay bound to the enzyme [2]. Omeprazole is mainly cleared by CYP2C19 and is a time-dependent inhibitor of that enzyme; lansoprazole is cleared by CYP3A and CYP2C19 [2]. A pharmacokinetic review describes omeprazole, lansoprazole and pantoprazole as all mainly metabolized by CYP2C19 [3]. In laboratory enzyme preparations, pantoprazole inhibited CYP2C19 less than omeprazole, with inhibition constants of 14 to 69 micromolar versus 2 to 6 micromolar [4].

Does Slowed Gastric Emptying Affect an Oral PPI?

This is the only place the two drugs could plausibly meet. The Trulicity label says dulaglutide delays gastric emptying and has the potential to reduce the rate of absorption of oral medications; the delay is dose-dependent, largest after the first dose and diminishes with later doses, and it is attenuated by the recommended dose escalation [1]. In clinical pharmacology studies, Trulicity 1.5 mg did not affect the absorption of the tested oral medications to a clinically relevant degree, and experience with concomitant oral medications at 3 mg and 4.5 mg is limited [1].

PPIs are delayed-release oral products [2]. The Trulicity interactions section does not name omeprazole or pantoprazole, so the size of any delay in PPI absorption is not stated there. The label's monitoring instruction points specifically to narrow-therapeutic-index oral drugs, and the only one it names is warfarin [1].

What the Trulicity Label Says to Watch For

Stomach and bowel effects are the most frequent reactions in the Trulicity trial tables. In the adult placebo-controlled pool (placebo 568 patients, 0.75 mg 836 patients, 1.5 mg 834 patients, mean exposure 23.8 weeks), nausea occurred in 5.3%, 12.4% and 21.1%; diarrhea in 6.7%, 8.9% and 12.6%; vomiting in 2.3%, 6.0% and 12.7%; and any GI reaction in 21%, 32% and 41% [1]. Treatment was stopped for GI reasons by 0.2%, 1.3% and 3.5% [1]. Severe GI reactions were reported by 1.4% of placebo patients, 2.2% of those on 0.75 mg and 4.3% of those on 1.5 mg [1]. The label also lists gastroesophageal reflux among reactions reported more often than placebo: 0.5% with placebo, 1.7% on 0.75 mg and 2.0% on 1.5 mg [1].

The label carries two GI-related warnings that matter more when nausea or vomiting is severe. Acute kidney injury from volume depletion has been reported, and the label says to monitor renal function in patients reporting reactions that could lead to dehydration, especially during starting and dose increases [1]. Trulicity is also not recommended in patients with severe gastroparesis [1]. The label says that if pancreatitis is suspected, Trulicity should be discontinued and appropriate management started [1].

What the PPI Labels Add

PPI warnings apply whether or not dulaglutide is on board. Hypomagnesemia is described as rare and reported in patients treated for at least three months, mostly after a year; serious cases included tetany, arrhythmias and seizures [2]. Vitamin B12 deficiency is tied in the labels to daily acid suppression over a long period, for example longer than three years, and the reports are called rare [2]. Clostridioides difficile diarrhea and bone fracture warnings are based on observational studies, and labels advise the lowest dose and shortest duration appropriate to the condition [2].

One case-control study of 25,956 adults with new vitamin B12 deficiency and 184,199 without it found an association between two or more years of PPI supply and B12 deficiency; it was observational and does not prove that PPI use caused the deficiency [5].

For people with diabetes and heart disease, the omeprazole and Nexium labels say to avoid concomitant clopidogrel and to consider another antiplatelet drug [2]. The pantoprazole and lansoprazole labels describe about a 14% fall in clopidogrel active-metabolite exposure and call it not clinically important. PPI labels also report raised INR and prothrombin time with warfarin and advise monitoring INR [2].

When Both Drugs Cause the Same Symptoms

The practical difficulty with this pair is attribution, not pharmacology. Diarrhea, nausea and abdominal pain appear in both the Trulicity and Nexium labels [1][2]. Headache, flatulence, constipation and dry mouth are listed as common adult reactions for Nexium, and vomiting and decreased appetite are listed for Trulicity [1][2]. If a PPI and Trulicity are started close together and stomach symptoms appear, it can be hard to tell which drug is responsible.

Practical Points for People on Both

Two label-based items are worth knowing. First, if warfarin is also in the picture, both labels call for attention: the Trulicity label names warfarin as a drug whose levels should be monitored and the PPI labels advise INR monitoring [1][2]. Second, when Trulicity is started in someone already taking insulin or a sulfonylurea, the label says to consider reducing the dose of the insulin or secretagogue to lower hypoglycemia risk [1].